Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
166-180 of 4724 results
Celgene to acquire Impact Biomedicines for about $7bn
By PBR Staff Writer
Global biopharmaceutical firm Celgene has agreed to acquire Impact Biomedicines in a deal worth about $7bn.
Drug Research > Drug Discovery & Development > News
Takeda proposes to buy cell therapy firm TiGenix for EUR520m
By PBR Staff Writer
Takeda Pharmaceutical has offered to acquire Belgium-based cell therapy company TiGenix for €520m to expand its late-stage gastroenterology pipeline and its footprint in the US specialty care market.
Drug Research > Drug Discovery & Development > News
BioNTech raises $270m in new round of funding
BioNTech, a company focused on developing personalized immunotherapies for cancer, has completed a $270m Series A round of financing.
Drug Research > Drug Discovery & Development > News
Sangamo, Pfizer collaborate to develop zinc finger protein gene therapy for ALS
Sangamo Therapeutics and Pfizer have collaborated for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
Drug Research > Drug Discovery & Development > News
NovaQuest Capital to buy Viamet Pharmaceuticals
NovaQuest Capital Management has agreed to acquire Viamet Pharmaceuticals, including its product candidate, VT-1161, which has completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection.
Drug Research > Drug Discovery & Development > News
Pear secures $50m funding to advance prescription digital therapeutics platform
Digital health firm Pear Therapeutics has completed a $50m Series B financing led by Singapore-headquartered investment firm Temasek.
Drug Research > Drug Discovery & Development > News
Summit signs deal with Eurofarma for Latin American rights to Ridinilazole
Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.
Drug Research > Drug Discovery & Development > News
vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei
vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.
Drug Research > Drug Discovery & Development > News
MilliporeSigma signs commercial supply agreement with bluebird bio for viral vector manufacturing
MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for use in potentially transformative gene therapies.
Drug Research > Drug Discovery & Development > News
Cancer Research UK, Celgene to collaborate on new anti-cancer treatments
By PBR Staff Writer
Cancer Research Technology (CRT), a subsidiary of Cancer Research UK, has entered into collaboration with American biopharmaceutical firm Celgene for the discovery, development and commercialization of new anti-cancer treatments.
Drug Research > Drug Discovery & Development > News
Asklepios BioPharmaceutical launches new portfolio company Actus Therapeutics
Asklepios BioPharmaceutical has formed Actus Therapeutics, a new portfolio company based on AskBio’s industry-leading gene therapy platform.
Drug Research > Drug Discovery & Development > News
GW Pharmaceuticals reacquires full rights of develop Sativex in US
GW Pharmaceuticals has terminated its previous license agreement with Otsuka Pharmaceutical in relation to Sativex (nabiximols) in the US.
Drug Research > Drug Discovery & Development > News
CMC Biologics signs development and manufacturing deal with Harpoon Therapeutics
CMC ICOS Biologics and Harpoon Therapeutics have signed an agreement to develop and manufacture HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of several human cancers.
Drug Research > Drug Discovery & Development > News
Aeonian Pharmaceuticals secures funding to develop mTORC1 inhibitors
Aeonian Pharmaceuticals, a San Francisco Bay Area-based biopharmaceutical company, has closed a seed financing round led by Apollo Ventures and Life Sciences Company.
Drug Research > Drug Discovery & Development > News
Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant
Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
Drug Research > Drug Discovery & Development > News
166-180 of 4724 results